High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

Philip Jay Bierman, J. R. Anderson, M. B. Freeman, Julie Marie Vose, A. Kessinger, M. R. Bishop, James Olen Armitage

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Background: The best results of conventional-dose salvage chemotherapy for Hodgkin's disease have been reported after first relapse. We evaluated the results of high-dose chemotherapy and autologous hematopoietic rescue for Hodgkin's disease patients who had relapsed from an initial chemotherapy-induced complete remission. Patients and methods: Eighty-five patients received high-dose cyclophosphamide, carmustine, and etoposide (CBV) followed by autologous bone marrow or peripheral blood stem cell transplantation. Results: Actuarial survival at five years was 51%, and failure-free survival was 40%. Failure-free survival at five years was 90% for patients who received no conventional-dose salvage chemotherapy prior to CBV. Failure-free survival of patients treated initially with a four-drug regimen was not significantly different than patients treated with seven/eight-drug regimens. Conclusion: These results appear to be better than those reported for conventional-dose salvage chemotherapy. High-dose therapy followed by autologous bone marrow or peripheral blood stem cell transplantation should be considered for any patient with relapsed Hodgkin's disease, regardless of the length of initial remission, or type of initial chemotherapy. Certain patients, especially those with minimal disease, may benefit by proceeding directly to transplantation after relapse, without first receiving conventional-dose salvage chemotherapy.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalAnnals of Oncology
Volume7
Issue number2
DOIs
StatePublished - Feb 1996

Fingerprint

Hodgkin Disease
Recurrence
Drug Therapy
Peripheral Blood Stem Cell Transplantation
Survival
Bone Marrow
Carmustine
Etoposide
Pharmaceutical Preparations
Cyclophosphamide
Transplantation

Keywords

  • Bone marrow transplantation
  • Drug therapy
  • Hematopoietic stem cell transplantation
  • Hodgkin's disease

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. / Bierman, Philip Jay; Anderson, J. R.; Freeman, M. B.; Vose, Julie Marie; Kessinger, A.; Bishop, M. R.; Armitage, James Olen.

In: Annals of Oncology, Vol. 7, No. 2, 02.1996, p. 151-156.

Research output: Contribution to journalArticle

@article{a681477d82cb4dd9ba9cfc1b4aba0b50,
title = "High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy",
abstract = "Background: The best results of conventional-dose salvage chemotherapy for Hodgkin's disease have been reported after first relapse. We evaluated the results of high-dose chemotherapy and autologous hematopoietic rescue for Hodgkin's disease patients who had relapsed from an initial chemotherapy-induced complete remission. Patients and methods: Eighty-five patients received high-dose cyclophosphamide, carmustine, and etoposide (CBV) followed by autologous bone marrow or peripheral blood stem cell transplantation. Results: Actuarial survival at five years was 51{\%}, and failure-free survival was 40{\%}. Failure-free survival at five years was 90{\%} for patients who received no conventional-dose salvage chemotherapy prior to CBV. Failure-free survival of patients treated initially with a four-drug regimen was not significantly different than patients treated with seven/eight-drug regimens. Conclusion: These results appear to be better than those reported for conventional-dose salvage chemotherapy. High-dose therapy followed by autologous bone marrow or peripheral blood stem cell transplantation should be considered for any patient with relapsed Hodgkin's disease, regardless of the length of initial remission, or type of initial chemotherapy. Certain patients, especially those with minimal disease, may benefit by proceeding directly to transplantation after relapse, without first receiving conventional-dose salvage chemotherapy.",
keywords = "Bone marrow transplantation, Drug therapy, Hematopoietic stem cell transplantation, Hodgkin's disease",
author = "Bierman, {Philip Jay} and Anderson, {J. R.} and Freeman, {M. B.} and Vose, {Julie Marie} and A. Kessinger and Bishop, {M. R.} and Armitage, {James Olen}",
year = "1996",
month = "2",
doi = "10.1093/oxfordjournals.annonc.a010542",
language = "English (US)",
volume = "7",
pages = "151--156",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

AU - Bierman, Philip Jay

AU - Anderson, J. R.

AU - Freeman, M. B.

AU - Vose, Julie Marie

AU - Kessinger, A.

AU - Bishop, M. R.

AU - Armitage, James Olen

PY - 1996/2

Y1 - 1996/2

N2 - Background: The best results of conventional-dose salvage chemotherapy for Hodgkin's disease have been reported after first relapse. We evaluated the results of high-dose chemotherapy and autologous hematopoietic rescue for Hodgkin's disease patients who had relapsed from an initial chemotherapy-induced complete remission. Patients and methods: Eighty-five patients received high-dose cyclophosphamide, carmustine, and etoposide (CBV) followed by autologous bone marrow or peripheral blood stem cell transplantation. Results: Actuarial survival at five years was 51%, and failure-free survival was 40%. Failure-free survival at five years was 90% for patients who received no conventional-dose salvage chemotherapy prior to CBV. Failure-free survival of patients treated initially with a four-drug regimen was not significantly different than patients treated with seven/eight-drug regimens. Conclusion: These results appear to be better than those reported for conventional-dose salvage chemotherapy. High-dose therapy followed by autologous bone marrow or peripheral blood stem cell transplantation should be considered for any patient with relapsed Hodgkin's disease, regardless of the length of initial remission, or type of initial chemotherapy. Certain patients, especially those with minimal disease, may benefit by proceeding directly to transplantation after relapse, without first receiving conventional-dose salvage chemotherapy.

AB - Background: The best results of conventional-dose salvage chemotherapy for Hodgkin's disease have been reported after first relapse. We evaluated the results of high-dose chemotherapy and autologous hematopoietic rescue for Hodgkin's disease patients who had relapsed from an initial chemotherapy-induced complete remission. Patients and methods: Eighty-five patients received high-dose cyclophosphamide, carmustine, and etoposide (CBV) followed by autologous bone marrow or peripheral blood stem cell transplantation. Results: Actuarial survival at five years was 51%, and failure-free survival was 40%. Failure-free survival at five years was 90% for patients who received no conventional-dose salvage chemotherapy prior to CBV. Failure-free survival of patients treated initially with a four-drug regimen was not significantly different than patients treated with seven/eight-drug regimens. Conclusion: These results appear to be better than those reported for conventional-dose salvage chemotherapy. High-dose therapy followed by autologous bone marrow or peripheral blood stem cell transplantation should be considered for any patient with relapsed Hodgkin's disease, regardless of the length of initial remission, or type of initial chemotherapy. Certain patients, especially those with minimal disease, may benefit by proceeding directly to transplantation after relapse, without first receiving conventional-dose salvage chemotherapy.

KW - Bone marrow transplantation

KW - Drug therapy

KW - Hematopoietic stem cell transplantation

KW - Hodgkin's disease

UR - http://www.scopus.com/inward/record.url?scp=0029918551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029918551&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.annonc.a010542

DO - 10.1093/oxfordjournals.annonc.a010542

M3 - Article

C2 - 8777171

AN - SCOPUS:0029918551

VL - 7

SP - 151

EP - 156

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -